Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026)

Bicara Therapeutics (BCAX) posted quarterly Capital Expenditures of $60000.0 for Q1 2026, down 74.79% quarter-over-quarter from $238000.0 in Q4 2025.

Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026) Analysis & Trends

Bicara Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $60000.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $60000.0; the TTM figure through Mar 2026 stood at $340000.0 (up 407.46% YoY), while the FY2025 annual figure was $280000.0, up 294.37% from the prior year.
Capital Expenditures for Q1 2026 stood at $60000.0, down from $238000.0 in the prior quarter.
The five-year high for Capital Expenditures was $436000.0 in Q4 2023, with the low at $4000.0 in Q1 2024.
The 4-year median for Capital Expenditures is $41000.0 (2024), against an average of $105875.0.
The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 90.83% in 2024, then soared 495.0% in 2025.
Bicara Therapeutics' Capital Expenditures stood at $436000.0 in 2023, then tumbled by 90.83% to $40000.0 in 2024, then jumped by 495.0% to $238000.0 in 2025, then slumped by 74.79% to $60000.0 in 2026.
Business Quant data shows BCAX's Capital Expenditures at $60000.0 in Q1 2026, $238000.0 in Q4 2025, and $42000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Bicara Therapeutics	1.60 Bn	1.60 Bn	-	60,000.00

Download Data